Proinsulin and its conversion intermediates in human pancreas and isolated islet tissue: Kinetics and steady-state analysis

Pancreas

Volumn 15, Issue 2, 1997, Pages 113-121

  Hou, X ^a   Ling, Z ^a   Zambre, Y ^a   Foriers, A ^a   Houssa, P ^b   Deberg, M ^b   Sodoyez, J C ^b   Hales, C N ^c   Van Der Auwera, B J ^a   Pipeleers, D ^a   Van Schravendijk, C ^a,d  

^a DIABETES RESEARCH CENTER   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Conversion intermediate; Diabetes; Insulin; Islets; Proinsulin

Indexed keywords

INSULIN; PROINSULIN; PROTEIN G;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOADSORPTION; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN CONTENT;

EID: 0030844159     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199708000-00002     Document Type: Article

References (38)

1. Davidson HW, Rhodes CJ, Hutton J. Intraorganellar calcium and pH control proinsulin cleavage in the pancreatic β cell via two distinct site-specific endopeptidases. Nature 1988;333:93-6.
2. Smeekens SP, Montag AG, Thomas G, et al. Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2 and PC3. Proc Natl Acad Sci USA 1992;89:8822-6.
3. Bailyes EM, Shennan KIJ, Seal AJ, et al. A member of the eukaryotic subtilisin family (PC3) has the enzymatic properties of the type 1 proinsulin-converting endopeptidase. Biochem J 1992;285: 391-4.
4. Bennet DL, Bailyes EM, Nielsen E, et al. Identification of the Type II proinsulin processing endopeptidase as PC2, a member of the eukaryote subtilisin family. J Biol Chem 1992;267:15229-36.
5. Orci L. The insulin factory: a tour of the plant surroundings and a visit to the assembly line. Diabetologia 1985;28:528-33.
6. Halban PA. Proinsulin processing in the regulated and the constitutive pathway. Diabetologia 1994;37 (Suppl 2):S65-72.
7. Sobey WJ, Beer SF, Carrington CA, et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 1989;260:535-41.
8. Temple RC, Carrington CA, Luzio SD, et al. Insulin deficiency in non-insulin dependent diabetes. Lancet 1989;1:293-5.
9. Mako ME, Starr JI, Rubenstein AH. Circulating proinsulin in patients with maturity onset diabetes. Am J Med 1977;63:865-9.
10. Porte D, Kahn SE. Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction? Diabetes 1989;38: 1333-6.
11. Rhodes CJ, Alarcon C. What β cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin conversion mechanism. Diabetes 1994;43:511-7.
12. Birkeland KI, Torjesen PA, Eriksson J, Vaaler S, Groop L. Hyperproinsulinemia of type II diabetes is not present before the development of hyperglycemia. Diabetes Care 1994;17:1307-10.
13. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP. Improved beta cell function, with reduction in secretion of intact and 32/33 split proinsulin, after dietary intervention in subjects with type 2 diabetes mellitus. Diabetes Med 1994;11(1):71-8.
14. 123F labelled proinsulin, split conversion intermediates and insulin in rat. Diabetologia 1988;31:848-54.
15. Van Schravendijk CFH, Foriers A, Hooghe-Peters EL, et al. Pancreatic hormone receptors on islet cells. Endocrinology 1985;117: 841-8.
16. Sodoyez JC, Koch M, Lemaire I, et al. Influence of affinity of antibodies upon their detection by liquid phase radiobinding assay and solid phase enzyme linked immunosorbent assay demonstration using monoclonal antibodies raised against rDNA human proinsulin. Diabetologia 1991;34:463-8.
17. Deberg M, Houssa P, Sodoyz-Goffaux F, Sodoyez JC. A new rapid and highly specific radioimmunoassay for "true" insulin. Diabetologia 1993;36(Suppl 1):A120.
18. Pipeleers DG, Schuit FC, In't Veld PA, et al. Interplay of nutrients and hormones in the regulation of insulin release. Endocrinology 1985;117:824-33.
19. Pipeleers D. Treatment of diabetes by islets cell transplantation. In: Baya C, ed. Biomedical and Health Research, Vol. 3. Adv. Med. Biol. IOS Press, 1994:185-97.
20. Warnock GL, Ellis DK, Cattral M, Untch D, Kneteman NM, Rajotte RV. Viable purified islets of Langerhans from collagenase-perfused human pancreas. Diabetes 1989;38 (Suppl 1):136-9.
21. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning, a laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989:9.16-9.19.
22. Sizonenko S, Irminger JC, Buhler L, Deng SP, Morel P, Halban PA. Kinetics of proinsulin conversion in human islets. Diabetes 1993;42:933-6.
23. Linde S, Roder ME, Hartling SG, Binder C, Welinder BS. Separation and quantification of serum proinsulin and proinsulin intermediates in human. J Chromatogr 1991;548:371-80.
24. Ostrega D, Polonsky K, Nagi D, et al. Measurement of proinsulin and intermediates. Validation of immunoassay methods by high performance liquid chromatography. Diabetes 1995;44:437-40.
25. Docherty K, Hutton JC. Carboxypeptidase activity in the insulin secretory granule. FEBS Lett 1983;162:137-41.
26. Given BD, Cohen RM, Shoelson SE, Frank BH, Rubenstein AH, Tager HS. Biochemical and clinical implications of proinsulin conversion intermediates. J Clin Invest 1985;76:1398-405.
27. Nakajima K, Morikawa A, Makino I. Natural history of β-cell dysfunction in spontaneously diabetic Chinese hamsters. Diabetes Res Clin Pract 1994;24(3):131-42.
28. Gadot M, Leibowitz G, Shafrir E, Cerasi E, Gross DJ, Kaiser N. Hyperproinsulinemia and insulin deficiency in the diabetic Psammomys obesus. Endocrinology 1994;135(2):610-6.
29. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP. Effect of sulphonylurea therapy on plasma insulin, intact and 32,33 split proinsulin in subjects with type 2 diabetes mellitus. Diabetes Med 1994;11(3):293-8.
30. Hales CN. The pathogenesis of NIDDM. Diabetologia 1994;37 (Suppl 2):S162-8.
31. Leahy JL, Halban PA, Weir GC. Relative hypersecretion of proinsulin in a rat model of NIDDM. Diabetes 1991;40:985-9.
32. Hales CN, Barker DJP. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992;35: 595-601.
33. Schuit FC, Kiekens R, Pipeleers DG. Measuring the balance between insulin synthesis and insulin release. Biochem Biophys Res Commun 1991;178:1182-7.
34. Chan SJ, Seino S, Gruppuso PA, Schwartz R, Steiner DF. A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia. Proc Natl Acad Sci USA 1987;88:2194-7.
35. Gruppuso PA, Gorden P, Kahn CR, Cornblath M, Zeller WP, Schwartz R. Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin. N Engl J Med 1984; 311:629-34.
36. Caroll RJ, Hammer RE, Chan SJ, Swift HH, Rubenstein AH, Steinder DF. A mutant proinsulin is secreted from islets of Langerhans in increased amounts via an unregulated pathway. Proc Natl Acad Sci USA 1988;85:8943-7.
37. Yoshida H, Ohagi S, Sanke T, Furuta H, Furuta M, Nanjo K. Association of the prohormone convenase 2 gene (PCSK2) on chromosome 20 with NIDDM in Japanese subjects. Diabetes 1995; 44:389-93.
38. Yudkin JS. Circulating proinsulinlike molecules. J Diabetes Comp 1993;7:113-23.